Resistant mutations in CML and Ph+ALL – role of ponatinib

Biologics: Targets and Therapy

Volumn 8, Issue , 2014, Pages 243-254

  Miller, Geoffrey D ^a   Bruno, Benjamin J ^a   Lim, Carol S ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

ARIAD; BCR ABL; Compound mutations; EPIC trial; PACE trial; Ph+ALL; T315I

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; DASATINIB; HG 78501; IMATINIB; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; REBASTINIB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ANTILEUKEMIC ACTIVITY; ARTERY THROMBOSIS; CELL PROLIFERATION; CHROMOSOME MUTATION; CHRONIC MYELOID LEUKEMIA; COLITIS; CONGESTIVE HEART FAILURE; DIARRHEA; DIFFUSE ALVEOLAR DAMAGE; DRUG ACTIVITY; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MARKETING; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERGLYCEMIA; HYPERLIPASEMIA; HYPERTRANSAMINASEMIA; HYPOPHOSPHATEMIA; LUNG DISEASE; LUNG FIBROSIS; MUCOSA INFLAMMATION; NEUTROPENIA; NONHUMAN; NONINFECTIOUS PNEUMONITIS; PANCREATITIS; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA; PNEUMONIA; PULMONARY HYPERTENSION; QT PROLONGATION; RASH; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; STOMATITIS; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA;

EID: 84908292829     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S50734     Document Type: Review

References (90)

1. Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983;306(5940):277-280.
2. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405):290-293.
3. Ren R. The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model. Oncogene. 2002;21(56):8629-8642.
4. Woessner DW, Lim CS, Deininger MW. Development of an effective therapy for chronic myelogenous leukemia. Cancer. 2011;17(6): 477-486.
5. Jeha S, Coustan-Smith E, Pei D, et al. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2014;120(10):1514-1519.
6. Thomas DA. Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges. Hematology/the Education Program of the American Society of Hematology. Hematology Am Soc Hematol Educ Program. 2007:435-443.
7. Lee HJ, Thompson JE, Wang ES, Wetzler M. Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives. Cancer. 2011;117(8):1583-1594.
8. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. The New England Journal of Medicine. 2001;344(14):1031-1037.
9. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. The New England Journal of Medicine. 2006;355(23):2408-2417.
10. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. The New England Journal of Medicine. 2001;344(14):1038-1042.
11. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol. 2014;89(5):547-556.
12. Shami PJ, Deininger M. Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. Leukemia. 2012;26(2): 214-224.
13. Prescribing Information for Synbrio (omacetaxine mepesuccinate). 2012.
14. Ottmann OG, Pfeifer H. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Hematology Am Soc Hematol Educ Program. 2009:371-381.
15. Deininger M, O'Brien SG, Guilhot F, et al. International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. Blood [abstract]. 2009;114.
16. Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood., 2014;123(4):494-500.
17. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012;26(10):2197-2203.
18. O'Hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nature reviews. Cancer. 2012;12(8):513-526.
19. Sierra JR, Cepero V, Giordano S. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Molecular Cancer. 2010;9:75.
20. Soverini S, Branford S, Nicolini FE, et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leukemia Research. 2014;38(1):10-20.
21. Shah NP, Skaggs BJ, Branford S, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. The Journal of Clinical Investigation. 2007;117(9):2562-2569.
22. Eide CA, Zabriskie MS, Adrian LT, et al. Resistance profiling of BCR-ABL compound mutations linked to tyrosine kinase inhibitor therapy failure in chronic myeloid leukemia [abstract]. Blood. 2011;118(21):1416.
23. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nature reviews. Cancer. 2009;9(1):28-39.
24. Khorashad JS, Kelley TW, Szankasi P, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood. 2013;121(3):489-498.
25. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401-412.
26. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Research. 2005; 65(11):4500-4505.
27. Zhou T, Parillon L, Li F, et al. Crystal structure of the T315I mutant of AbI kinase. Chemical Biology and Drug Design. 2007;70(3):171-181.
28. Buffa P, Romano C, Pandini A, et al. BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology. 2014;28(3): 1221-1236.
29. Zhou T, Commodore L, Huang WS, et al. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chemical Biology And Drug Design. 2011;77(1):1-11.
30. Huang WS, Metcalf CA, Sundaramoorthi R, et al. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-y l)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. Journal of Medicinal Chemistry. 2010;53(12):4701-4719.
31. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. The New England Journal of Medicine. 2012;367(22):2075-2088.
32. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. The New England Journal Of Medicine. 2013;369(19):1783-1796.
33. Quintas-Cardama A. Ponatinib in Philadelphia chromosome-positive leukemias. The New England Journal of Medicine. 2014;370(6):577.
34. Mauro MJ, Cortes JE, Kim DW. Multivariate analyses of the clinical and molecular parameters associated with efficacy and safety in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) treated with ponatinib in the PACE trial [Abstract 3747]. Blood. 2012;120.
35. Deininger M, Cortes JE, Kim DW. Impact of baseline mutations on response to ponatinib and end of treatment mutation analysis in patients with chronic myeloid leukemia [Abstract 7001]. American Society of Clinical Oncology. 2013;31(Suppl).
36. Chustecka Z. FDA Approves Ponatinib for Rare Leukemias. Medscape Medical News. December 14, 2012.
37. Khoury HJ, Cortes JE, Kim DW. Analysis of the cardiovascular risk profile of Ph+ leukemia patients treated with ponatinib [Abstract 7048]. American Society of Clinical Oncology. 2013;31(Suppl).
38. Prasad V, Mailankody S. The accelerated approval of oncologic drugs: lessons from ponatinib. JAMA. 2014;311(4):353-354.
39. Mulcahy N. Leukemia Drug Ponatinib (Iclusig) Pulled From Market. Medscape Medical News. October 31, 2013.
40. Ariad Ends Phase III Leukemia Drug Trial. Genetic Engineering and Biotechnology News. October 18, 2013.
41. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11): 1029-1035.
42. Bonifazi F, De Vivo A, Rosti G, et al. Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon. Italian Cooperative Study Group on Chronic Myeloid Leukaemia. Br J Haematol. 2000;111(2):587-595.
43. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26(20):3358-3363.
44. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841-851.
45. ICLUSIG® (ponatinib) tablets for oral use. [prescribing information]. Cambridge: ARIAD Pharmaceuticals, Inc.; 2013.
46. Preuner S, Mitterbauer G, Mannhalter C, et al. Quantitative monitoring of BCR/ABL1 mutants for surveillance of subclone-evolution, -expansion, and -depletion in chronic myeloid leukaemia. Eur J Cancer. 2012;48(2):233-236.
47. Kastner R, Zopf A, Preuner S, et al. Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing. Eur J Cancer. 2014;50(4): 793-800.
48. Frankfurt O, Licht JD. Ponatinib-a step forward in overcoming resistance in chronic myeloid leukemia. Clin Cancer Res. 2013;19(21): 5828-5834.
49. Dixon AS, Miller GD, Bruno BJ, et al. Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis. Mol Pharm. 2012;9(1):187-195.
50. Miller GD, Woessner DW, Sirch MJ, Lim CS. Multidomain Targeting of Bcr-Abl by Disruption of Oligomerization and Tyrosine Kinase Inhibition: Toward Eradication of CML. Mol Pharm. 2013;10(9): 3475-3483.
51. Woessner DW, Lim CS. Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation. Mol Pharm. 2013;10(1): 270-277.
52. Eiring AM, Kraft IL, Page BDG, et al. BP5-087, a Novel STAT3 Inhibitor, Combines With BCR-ABL1 Inhibition To Overcome Kinase-Independent Resistance In Chronic Myeloid Leukemia. Presented at: 55th ASH Annual Meeting and Exposition; December 7-10, 2013; New Orleans, LA. Abstract.
53. Dao KH, Tyner JW. Next-generation medicine: combining BCR-ABL and Hedgehog-targeted therapies. Clin Cancer Res. 2013;19(6): 1309-1311.
54. Gozgit JM, Squillace RM, Wongchenko MJ, et al. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother Pharmacol. 2013;71(5):1315-1323.
55. Eide CA, Adrian LT, Tyner JW, et al. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res. 2011;71(9):3189-3195.
56. Clinical Trial NCT00827138: Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation). ClinicalTrials.gov. 2013.
57. Weisberg E, Choi HG, Ray A, et al. Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood. 2010;115(21):4206-4216.
58. Clinical Trial NCT01431664: AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia. ClinicalTrials.gov. 2014.
59. Tanaka R, Squires MS, Kimura S, et al. Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells. Blood. 2010;116(12):2089-2095.
60. Hantschel O, Grebien F, Superti-Furga G. The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL. Cancer Res. 2012;72(19):4890-4895.
61. Chomel JC, Turhan AG. Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget. 2011;2(9):713-727.
62. Brooks C, Macri V, Albini A, Bergstein I, Rowinsky E. SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Possesses Preclinical Cytotoxic Activity Against Chronic Eosinophilic Leukemia. Blood. 2013;21(122).
63. Konopleva M. SL-401, a targeted therapeutic directed at the interleukin-3 receptor, inhibits the growth of leukemia stem cells from patients with CML. Presented at: 15th International Conference on CML; September 26, 2013; Estoril, Portugal.
64. De Falco V, Buonocore P, Muthu M, et al. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. J Clin Endocrinol Metab. 2013;98(5):E811-E819.
65. Gozgit JM, Wong MJ, Moran L, et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther. 2012;11(3):690-699.
66. Gozgit JM, Wong MJ, Wardwell S, et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther. 2011;10(6):1028-1035.
67. Ren M, Qin H, Ren R, Cowell JK. Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities. Leukemia. 2013;27(1):32-40.
68. Smith CC, Lasater EA, Zhu X, et al. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood. 2013;121(16):3165-3171.
69. Clinical Trial NCT01761747: Ponatinib for Squamous Cell Lung and Head and Neck Cancers. ClinicalTrials.gov. 2014.
70. Clinical Trial NCT01888562: Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma. ClinicalTrials.gov. 2014.
71. Clinical Trial NCT01935336: Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers. ClinicalTrials.gov. 2014.
72. Clinical Trial NCT01813734: Ponatinib in Advanced NSCLC w/RET Translocations. ClinicalTrials.gov. 2014.
73. Clinical Trial NCT01838642: Ponatinib for Advanced Medullary Thyroid Cancer. ClinicalTrials.gov. 2014.
74. Clinical Trial NCT01874665: A Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor. ClinicalTrials.gov. 2014.
75. Rose SE, Shakespeare W. Personal correspondence with ARIAD Pharmaceuticals, Inc. June 9, 2014.
76. Clinical Trial NCT00660920: Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies. ClinicalTrials.gov. 2013.
77. Clinical Trial NCT01207440: PONATINIB for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) (PACE). ClinicalTrials.gov. 2013.
78. Clinical Trial NCT01650805: Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC). ClinicalTrials.gov. 2014.
79. Inman S. Late-stage ponatinib study discontinued. OncLive. Epub October 18, 2013.
80. Nelson R. Ponatinib (Iclusig) returns to market, with a few caveats. Medscape Medical News. December 20, 2013.
81. Greuber EK, Smith-Pearson P, Wang J, Pendergast AM. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nature Reviews Cancer. 2013;13(8):559-571.
82. Stages of Chronic Myeloid Leukemia [webpage on the Internet]. National Cancer Institute; 2014 [updated June 27, 2014]. Available from: http://www.cancer.gov/cancertopics/pdq/treatment/CML/Patient/page2. Accessed September 19, 2014.
83. Chronic Myeloid Leukaemia [webpage on the Internet]. Patient; 2014 [updated July 19, 2012]. Available from: http://www.patient.co.uk/doctor/chronic-myeloid-leukaemia-pro#. Accessed September 19, 2014.
84. How is chronic myeloid leukemia classified? [webpage on the Internet]. American Cancer Society; 2014 [updated February 10, 2014]. Available from: http://www.cancer.org/cancer/leukemia-chronicmyeloidcml/detailedguide/leukemia-chronic-myeloid-myelogenous-staging. Accessed July 14, 2014.
85. Clopton J. Feeling Sick With CML: Coping With Later Phases. WebMD. 2014.
86. Staging for chronic myeloid leukemia (CML) [webpage on the Internet]. London: Cancer Research UK; 2014. Available from: http://www.cancerresearchuk.org/about-cancer/type/cml/treatment/staging-for-chronic-myeloid-leukaemia. Accessed July 14, 2014.
87. Kantarjian H, Schiffer C, Jones D, Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood. 2008;111(4):1774-1780.
88. GLEEVEC (imatinib mesylate) tablets for oral use. [prescribing information]. East Hanover: Novartis Pharmaceuticals Corporation; 2014.
89. SPRYCEL (dasatinib) tablet for oral use. [prescribing information]. Princeton: Bristol-Meyers Squibb Company; 2010.
90. TASIGNA (nilotinib) Capsules for oral use. [prescribing information]. East Hanover: Novartis Pharmaceuticals Corporation; 2014.